Literature DB >> 23303673

Proteolysis breaks tolerance toward intact α345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for α345NC1 hexamers.

Florina Olaru1, Xu-Ping Wang, Wentian Luo, Linna Ge, Jeffrey H Miner, Sandra Kleinau, Xochiquetzal J Geiger, Andrew Wasiluk, Laurence Heidet, A Richard Kitching, Dorin-Bogdan Borza.   

Abstract

Goodpasture disease is an autoimmune kidney disease mediated by autoantibodies against noncollagenous domain 1 (NC1) monomers of α3(IV) collagen that bind to the glomerular basement membrane (GBM), usually causing rapidly progressive glomerulonephritis (GN). We identified a novel type of human IgG4-restricted anti-GBM autoantibodies associated with mild nonprogressive GN, which specifically targeted α345NC1 hexamers but not α3NC1 monomers. The mechanisms eliciting these anti-GBM autoantibodies were investigated in mouse models recapitulating this phenotype. Wild-type and FcγRIIB(-/-) mice immunized with autologous murine GBM NC1 hexamers produced mouse IgG1-restricted autoantibodies specific for α345NC1 hexamers, which bound to the GBM in vivo but did not cause GN. In these mice, intact collagen IV from murine GBM was not immunogenic. However, in Col4a3(-/-) Alport mice, both intact collagen IV and NC1 hexamers from murine GBM elicited IgG Abs specific for α345NC1 hexamers, which were not subclass restricted. As heterologous Ag in COL4A3-humanized mice, murine GBM NC1 hexamers elicited mouse IgG1, IgG2a, and IgG2b autoantibodies specific for α345NC1 hexamers and induced anti-GBM Ab GN. These findings indicate that tolerance toward autologous intact α345(IV) collagen is established in hosts expressing this Ag, even though autoreactive B cells specific for α345NC1 hexamers are not purged from their repertoire. Proteolysis selectively breaches this tolerance by generating autoimmunogenic α345NC1 hexamers. This provides a mechanism eliciting autoantibodies specific for α345NC1 hexamers, which are restricted to noninflammatory IgG subclasses and are nonnephritogenic. In Alport syndrome, lack of tolerance toward α345(IV) collagen promotes production of alloantibodies to α345NC1 hexamers, including proinflammatory IgG subclasses that mediate posttransplant anti-GBM nephritis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303673      PMCID: PMC3563930          DOI: 10.4049/jimmunol.1202204

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  The goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain.

Authors:  D B Borza; K O Netzer; A Leinonen; P Todd; J Cervera; J Saus; B G Hudson
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

2.  Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains.

Authors:  A Boutaud; D B Borza; O Bondar; S Gunwar; K O Netzer; N Singh; Y Ninomiya; Y Sado; M E Noelken; B G Hudson
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

3.  Goodpasture's disease.

Authors:  A D Salama; J B Levy; L Lightstone; C D Pusey
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

4.  Quaternary organization of the goodpasture autoantigen, the alpha 3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intrapromoter interactions with the alpha4 and alpha5 NC1 domains.

Authors:  Dorin-Bogdan Borza; Olga Bondar; Parvin Todd; Munirathinam Sundaramoorthy; Yoshikazu Sado; Yoshifumi Ninomiya; Billy G Hudson
Journal:  J Biol Chem       Date:  2002-08-21       Impact factor: 5.157

5.  The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice.

Authors:  Helmut Hopfer; Ruth Maron; Ulrike Butzmann; Udo Helmchen; Howard L Weiner; Raghu Kalluri
Journal:  FASEB J       Date:  2003-05       Impact factor: 5.191

6.  Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome.

Authors:  R Kalluri; L G Cantley; D Kerjaschki; E G Neilson
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

7.  Characterization of the renal CD4+ T-cell response in experimental autoimmune glomerulonephritis.

Authors:  Helmut Hopfer; Julia Holzer; Stefanie Hünemörder; Hans-Joachim Paust; Marlies Sachs; Catherine Meyer-Schwesinger; Jan-Eric Turner; Ulf Panzer; Hans-Willi Mittrücker
Journal:  Kidney Int       Date:  2012-03-21       Impact factor: 10.612

8.  Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.

Authors:  J B Levy; A N Turner; A J Rees; C D Pusey
Journal:  Ann Intern Med       Date:  2001-06-05       Impact factor: 25.391

9.  Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome.

Authors:  Kaya L Andrews; Jacqueline L Mudd; Cong Li; Jeffrey H Miner
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

10.  Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease.

Authors:  A Nakamura; T Yuasa; A Ujike; M Ono; T Nukiwa; J V Ravetch; T Takai
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

View more
  10 in total

Review 1.  Basement membranes and autoimmune diseases.

Authors:  Mary H Foster
Journal:  Matrix Biol       Date:  2016-08-02       Impact factor: 11.583

2.  Maternal alloimmune IgG causes anti-glomerular basement membrane disease in perinatal transgenic mice that express human laminin α5.

Authors:  Dale R Abrahamson; Brooke M Steenhard; Larysa Stroganova; Adrian Zelenchuk; Patricia L St John; Margaret G Petroff; Manuel Patarroyo; Dorin Bogdan Borza
Journal:  Kidney Int       Date:  2019-07-10       Impact factor: 10.612

3.  Neonatal Fc receptor promotes immune complex-mediated glomerular disease.

Authors:  Florina Olaru; Wentian Luo; Hani Suleiman; Patricia L St John; Linna Ge; Adam R Mezo; Andrey S Shaw; Dale R Abrahamson; Jeffrey H Miner; Dorin-Bogdan Borza
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

Review 4.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

Review 5.  The immune system and kidney disease: basic concepts and clinical implications.

Authors:  Christian Kurts; Ulf Panzer; Hans-Joachim Anders; Andrew J Rees
Journal:  Nat Rev Immunol       Date:  2013-09-16       Impact factor: 53.106

6.  Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease.

Authors:  Cong-Rong Shen; Xiao-Yu Jia; Wentian Luo; Florina Olaru; Zhao Cui; Ming-Hui Zhao; Dorin-Bogdan Borza
Journal:  J Am Soc Nephrol       Date:  2021-04-23       Impact factor: 14.978

7.  Factors Associated With Pathogenicity of Anti-Glomerular Basal Membrane Antibodies: A Case Report.

Authors:  Rime Ossman; David Buob; Thomas Hellmark; Isabelle Brocheriou; Julie Peltier; Ryad Tamouza; Karine Dahan; Alexandre Hertig; Eric Rondeau; Pierre Galichon
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

8.  Atypical anti-glomerular basement membrane disease.

Authors:  Megan L Troxell; Donald C Houghton
Journal:  Clin Kidney J       Date:  2015-12-30

9.  Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy.

Authors:  Wentian Luo; Florina Olaru; Jeffrey H Miner; Laurence H Beck; Johan van der Vlag; Joshua M Thurman; Dorin-Bogdan Borza
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

10.  A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis.

Authors:  Barbora Sporinova; Susanna A McRae; Daniel A Muruve; Marvin J Fritzler; Samih H Nasr; Alex C Chin; Hallgrimur Benediktsson
Journal:  BMC Nephrol       Date:  2019-01-31       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.